Trial effectiveness | Uptake of intervention | Population impact | |||||||
---|---|---|---|---|---|---|---|---|---|
Intervention | Total event rate in intervention group | Total event rate in control group | Summary Relative Risk (95% CI) | Relative Risk Reduction (RRR;1-RR) | Total number of participating GPs | Total number of potential participating GPs | Population Uptake (95% CI) | Relative risk reduction (RRR × Uptake) | Ranking |
Delayed prescribing | 255/817 | 790/847 | 0.36 (0.27–0.48) | 64% | 48 | 255d | 19% (14–24%) | 12.0% | 1 |
Procalcitonin | 117/507 | 320/501 | 0.39 (0.17–0.86) | 61% | 53 | 345 | 15% (12–19%) | 9.4% | 2 |
CRP | 631/1685 | 785/1599 | 0.78 (0.66–0.92) | 22% | 35 | 125 | 28% (20% – 36%) | 6.2% | 3 |
Shared decision making | 5236a | 4936a | 0.61 (0.55–0.68) | 39% | 281b | 3389b | 9.5% (0–20%)c | 3.7% | 4 |